Drug Profile
Research programme: Alzheimer's disease antibody therapeutics - Alector
Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Adimab; Alector
- Developer Alector
- Class Antibodies; Antidementias
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 31 Dec 2021 Alector enters into a collaboration agreement with Adimab for antibody engineering research programs before December 2021
- 31 Dec 2019 Alector enters into a collaboration agreement with Adimab to discover and optimize antibodies before December 2019
- 28 Jul 2018 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)